Melissa P. Upton, MD
Department of Pathology, University of Washington, Seattle

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online Educational Activity and Post Exam

Physician Competencies: Medical Knowledge, Patient Care & Procedural Skills, Practice-Based Learning & Improvement

Eligibility for CME/CMLE credit: Max three attempts. You will have a maximum of three attempts to meet the following criteria:

• Module ≥80% = CME credit
• Module <80% = No CME credit, after a maximum of three attempts

Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME credit.)

Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. 

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CE activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Disclosure Information.
2. Review the Technical Considerations.
3. Click Go to Course to view an overview of the modules in this course.
4. Click Access to begin the course.
5. Review the Educational Activity.
6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
7. Submit the course Evaluation.
8. Enter the maximum number of credits offered and click Claim CME to register credit.

Disclosure Information​
The Journal CME editor has no relevant financial relationships with ineligible companies to disclose.

Technical Considerations

Release Date: 8/16/2024 
Review Date:
Expiration Date: 8/16/2027 

• Compare the utility and application of various testing modalities for assessing residual disease in TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

• List clinical features of TP53-mutated AML and MDS, and discuss limitations of applying measurable residual disease flow cytometry (MRD-FC) and molecular testing in evaluating residual disease.

• Describe the methods used by the authors for applying p53 immunohistochemistry for rapid assessment of residual disease in TP53-mutated AML and MDS.